A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells

Eur J Immunol. 2001 Jun;31(6):1910-6. doi: 10.1002/1521-4141(200106)31:6<1910::aid-immu1910>3.0.co;2-k.


Antigens encoded by MAGE genes and recognized by T cells are of interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Several MAGE-1 peptide that are recognized by CD8(+) cytolytic T lymphocytes have been used in therapeutic vaccination trials. To obtain anti-tumor immune response, vaccines combining peptides recognized by CD8(+) and peptides recognized by CD4(+) T cells might be optimal. We focused therefore on the identification of MAGE peptides recognized by CD4(+) T cells. We report here the identification of MAGE-1 epitope EYVIKVSARVRF, which is presented to CD4(+) T lymphocytes by HLA-DR15. This HLA allele is present in 29 % of Asians and 17 % of Caucasians.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen Presentation / immunology
  • Antigens, Neoplasm
  • CD4-Positive T-Lymphocytes / immunology*
  • Cell Line, Transformed
  • HLA-DR Antigens / immunology*
  • HLA-DR Serological Subtypes
  • Humans
  • Melanoma-Specific Antigens
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology*
  • Peptides / immunology
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Tumor Cells, Cultured


  • Antigens, Neoplasm
  • HLA-DR Antigens
  • HLA-DR Serological Subtypes
  • HLA-DR15 antigen
  • MAGEA1 protein, human
  • Melanoma-Specific Antigens
  • Neoplasm Proteins
  • Peptides
  • Recombinant Fusion Proteins